JAK

Actions
  1. Inhibitor (37)


Items 1 to 25 of 47 total

per page
Page:
  1. 1
  2. 2

Set Descending Direction
Catalog No. Product Name Product Information
A15361

1,2,3,4,5,6-Hexabromocyclohexane

1,2,3,4,5,6-Hexabromocyclohexane is a potent and specific inhibitor of JAK2 autophosphorylation.
A10095

AT9283

AT9283 inhibits aurora kinase A and B and targets other tyrosine and serine/threonine kinases associated with myeloid cell proliferation.
A10104

AZ-960

AZ-960 is a potent, selective and ATP competitive JAK2 inhibitor that inhibits JAK2 kinase with a Ki of 0.45 nM in vitro and induces growth arrest and apoptosis in adult T-cell leukemia (ATL) cell.
A10110

AZD1480

AZD1480 is a novel potent small JAK2 inhibitor with an IC50 of 0.26 nM.
A11329

Baricitinib (LY3009104)

Baricitinib, also known as INCB028050 or LY3009104, is a selective orally bioavailable JAK1/JAK2 inhibitor with nanomolar potency against JAK1 (5.9 nM) and JAK2 (5.7 nM).
A15014

Baricitinib phosphate

Baricitinib phosphate is a selective JAK1 and JAK2 inhibitor with IC50 of 5.9 nM and 5.7 nM, ~70 and ~10-fold selective versus JAK3 and Tyk2, no inhibition to c-Met and Chk2.
A11241

BMS-911543

BMS-911543 is an orally available small molecule targeting a subset of Janus-associated kinase (JAK) with potential antineoplastic activity.
A12808

CEP33779

CEP33779 is a selective JAK2 inhibitor with IC50 of 1.8 nM.
A15362

Cercosporamide

Cercosporamide, an usnic amide, was originally identified in Cercosporidium henningsii as a host-selective phytotoxin and broad-spectrum antifungal agent and is a potent inhibitor of MAP-kinase interacting kinase-2 (Mnk2; IC50 = 11 nM), JAK3 (IC50 = 31), and Mnk1 (IC50 = 116 nM).
A10241

CP-690550 (Tofacitinib citrate)

CP-690550 (Tofacitinib citrate) is an orally available, highly selective inhibitor of the Janus kinase (JAK) family of enzymes.
A14665

Cucurbitacin B

Cucurbitacin B, a natural triterpenoid is well-known for its strong anticancer activity, and recent studies showed that the compound inhibits JAK/STAT3 pathway.
A15363

Cucurbitacin I

Cucurbitacin I, Cucumis sativus L. has been found to suppress levels of phosphotyrosine Stat3 (signal transducer and activator of transcription 3) in v-Src-transformed NIH 3T3 cells.
A10247

Curcumol

Curcumol induces apoptosis via caspases-independent mitochondrial pathway in human lung adenocarcinoma ASTC-a-1 cells.
A10263

Cyt387 (Momelotinib)

CYT387 is an inhibitor of Janus kinases JAK1 and JAK2, acting as an ATP competitor with IC50 values of 11 and 18 nM, respectively.
A15056

CYT387 sulfate salt

CYT387 sulfate salt is an ATP-competitive inhibitor of JAK1/JAK2 with IC50 of 11 nM/18 nM, ~10-fold selectivity versus JAK3.
A14012

Decernotinib

Decernotinib is an oral, selective Janus kinase 3 (JAK3) inhibitor being developed by Vertex.
A14232

Filgotinib

Filgotinib is a selective JAK1 inhibitor with IC50 of 10 nM, 28 nM, 810 nM, and 116 nM for JAK1, JAK2, JAK3, and TYK2, respectively.
A15911

FLLL32

FLLL32 is a potent JAK2/STAT3 inhibitor with IC50 of <5 uM.
A13162

GLPG0634

GLPG0634 is an orally-available, selective inhibitor of JAK1 (Janus kinase 1) being developed by Galapagos for the treatment of rheumatoid arthritis and potentially other inflammatory diseases.
A11041

INCB018424 (Ruxolitinib)

INCB018424 is a potent and selective inhibitor of Janus-associated kinase (JAK) 1 and 2, with IC50 to be 2.7, 4.5 and 332 nM for JAK1, JAK2 and JAK3 respectively;
A14390

INCB39110 (Itacitinib)

INCB39110 is a potent JAK1 tyrosine kinase inhibitor, which is currently in Phase II trials for the treatment of rheumatoid arthritis, myelofibrosis, rheumatoid arthritis and plaque psoriasis.
A15134

JANEX-1

Janex-1 is a cell-permeable, reversible, potent, ATP-competitive, and specific inhibitor of JAK3 (IC50 = 78 ??M); has no effect on JAK1, JAK2, or Zap/Syk or SRC tyrosine kinases.
A10546

LY2784544 (Gandotinib)

LY2784544 is identified as being highly selective for JAK2-V617F and has advanced into human clinical trials for the treatment of several myeloproliferative disorders.
A16224

NS-018

NS-018 is an orally bioavailable, small molecule inhibitor of Janus-associated kinase 2 (JAK2) and Src-family kinases, with potential antineoplastic activity.
A16225

NS-018 hydrochloride

NS-018 hydrochloride is a novel highly selective JAK2 inhibitor.

Items 1 to 25 of 47 total

per page
Page:
  1. 1
  2. 2

Set Descending Direction